Travellers' diarrhoea - solidifying our knowledgebase.

PURPOSE OF REVIEW

Travellers' diarrhoea remains one of the most common diseases amongst international travellers. However, significant uncertainty remains about the most effective strategies for its prevention and management. This review summarises recent advances in travellers' diarrhoea epidemiology, diagnostics, and management, focusing on new severity definitions, the impact of molecular diagnostics, antimicrobial resistance, and postinfectious sequelae.

RECENT FINDINGS

The incidence of travellers' diarrhoea remains substantial although much of this is attributable to mild disease. Viral travellers' diarrhoea is more frequently recognised due to the improved sensitivity of molecular diagnostics. Advances in microbiome research reveal both acute and persistent disruption to the microbiota following travellers' diarrhoea and antibiotic use. New severity definitions incorporating functional impairment offer improved clinical relevance but consensus over use remains lacking. Nonabsorptive antibiotics and probiotics show promise for treatment and prevention, but antimicrobial resistance continues to rise. Postinfectious irritable bowel syndrome (IBS) significantly impacts the recovery of some travellers' diarrhoea patients.

SUMMARY

Consensus on severity definitions is needed to support successful research into new vaccines and therapeutics. Surveillance of resistance, research into microbiome disruption and recovery, and development of vaccines and probiotics are key priorities. Better pathophysiological understanding and new intervention strategies are required to help alleviate the suffering of post-travellers' diarrhoea IBS.

Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.